相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting
Christopher D. Pilcher et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2017)
Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa
Mark W. Sonderup et al.
AIDS (2016)
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs
Stefanie Hennig et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
M. S. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial
Sydney Rosen et al.
PLOS MEDICINE (2016)
Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa
Christine Njuguna et al.
AIDS RESEARCH AND THERAPY (2016)
Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study
Alberto M. La Rosa et al.
LANCET HIV (2016)
Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial
Gideon Amanyire et al.
LANCET HIV (2016)
Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials
Jiangzhou You et al.
PLOS ONE (2016)
Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis A Systematic Review and Meta-analysis
Olalekan A. Uthman et al.
ANNALS OF INTERNAL MEDICINE (2015)
Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
Sharon Walmsley et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
The future role of CD4 cell count for monitoring antiretroviral therapy
Nathan Ford et al.
LANCET INFECTIOUS DISEASES (2015)
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
Jens D. Lundgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
Christine Danel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study
Graeme Meintjes et al.
AIDS RESEARCH AND THERAPY (2015)
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study
Jean-Michel Molina et al.
LANCET HIV (2015)
Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection
Trevor A. Crowell et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Social and ethical implications of HIV cure research
Joseph D. Tucker et al.
AIDS (2014)
Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America
Gregory M. Lucas et al.
CLINICAL INFECTIOUS DISEASES (2014)
Virological efficacy of abacavir: systematic review and meta-analysis
Mario Cruciani et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Evidence for Innate Immune System Activation in HIV Type 1-Infected Elite Controllers
Sonya Krishnan et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial
Molebogeng X. Rangaka et al.
LANCET (2014)
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial
Rebekah L. Puls et al.
LANCET (2014)
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial
Beatriz Grinsztejn et al.
LANCET INFECTIOUS DISEASES (2014)
Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa
Nicholas I. Paton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
David R. Boulware et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials
Calvin J. Cohen et al.
AIDS (2013)
Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review
Timothy Eley et al.
ANTIVIRAL THERAPY (2013)
Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy: Implications for Treatment Guidelines
Kristine B. Patterson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Pedro Cahn et al.
LANCET (2013)
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
Francois Raffi et al.
LANCET (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug Reaction
Renee de Waal et al.
PLOS ONE (2013)
Consensus statement: Management of drug-induced liver injury in HIV-positive patients treated for TB
E Jong et al.
SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE (2013)
Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies
Leigh F. Johnson et al.
PLOS MEDICINE (2013)
Primary Drug Resistance in South Africa: Data from 10 Years of Surveys
Justen Manasa et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2012)
Surveillance of Transmitted HIV-1 Drug Resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009
G. M. Hunt et al.
CLINICAL INFECTIOUS DISEASES (2012)
Should We Treat Acute HIV Infection?
Meagan O'Brien et al.
CURRENT HIV/AIDS REPORTS (2012)
Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data
Mario Cruciani et al.
AIDS (2011)
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis
Nathan Ford et al.
AIDS (2011)
No Risk of Myocardial Infarction Associated With Initial Antiretroviral Treatment Containing Abacavir: Short and Long-Term Results from ACTG A5001/ALLRT
Heather J. Ribaudo et al.
CLINICAL INFECTIOUS DISEASES (2011)
Immunologic Criteria Are Poor Predictors of Virologic Outcome: Implications for HIV Treatment Monitoring in Resource-Limited Settings
Holly E. Rawizza et al.
CLINICAL INFECTIOUS DISEASES (2011)
Timing of Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus (HIV)-Associated Tuberculous Meningitis
M. Estee Toeroek et al.
CLINICAL INFECTIOUS DISEASES (2011)
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
Myron S. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies
Haileyesus Getahun et al.
PLOS MEDICINE (2011)
Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy
Amelie Guihot et al.
AIDS (2010)
Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth
M. J. Sikora et al.
HIV MEDICINE (2010)
Mortality Associated With Discordant Responses to Antiretroviral Therapy in Resource-Constrained Settings
Suely Hiromi Tuboi et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study
Jean-Michel Molina et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
A CD4+ Cell Count <200 Cells per Cubic Millimeter at 2 Years After Initiation of Combination Antiretroviral Therapy Is Associated With Increased Mortality in HIV-Infected Individuals With Viral Suppression
Mona R. Loutfy et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions
Lewis J. Haddow et al.
LANCET INFECTIOUS DISEASES (2010)
High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial
Y. Yazdanpanah et al.
CLINICAL INFECTIOUS DISEASES (2009)
Will Etravirine Work in Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor-Based Treatment in Southern Africa?
Wendy S. Stevens et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2009)
Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial
Andrew R. Zolopa et al.
PLOS ONE (2009)
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study:: a multi-cohort collaboration
Caroline A. Sabin et al.
LANCET (2008)
Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings
Graeme Meintjes et al.
LANCET INFECTIOUS DISEASES (2008)
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study
A. Mocroft et al.
LANCET (2007)
Virologic efficacy of boosted double versus boosted single protease inhibitor therapy
Maya L. Petersen et al.
AIDS (2007)
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
M Johnson et al.
AIDS (2006)
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy
GR Kaufmann et al.
CLINICAL INFECTIOUS DISEASES (2005)
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
B Ledergerber et al.
LANCET (2004)
The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy
CJ Smith et al.
AIDS (2003)
分享论文
